Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma
IntroductionPlasmablastic lymphoma (PBL) is a rare and highly aggressive form of non-Hodgkin lymphoma that is associated with a poor prognosis. Traditional chemotherapy has demonstrated limited efficacy for PBL. There is currently no standard treatment for patients with refractory or relapsing PBL....
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2025-10-01
|
| Edice: | Frontiers in Immunology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1697566/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|